Weight-Loss Drugs Cut Heart Attack and Stroke Risk
GLP-1 drugs help people lose weight and control blood sugar. New research reveals another major advantage. These medications also protect the heart. They lower the risk of heart attacks and strokes. The findings come from a large‑scale analysis.
Strong Evidence from 90,000 Patients
Scientists at Anglia Ruskin University reviewed 11 major trials. The studies followed over 90,000 patients for at least one year. People taking GLP‑1 drugs had a 13 percent lower risk of serious cardiovascular events. This includes heart attack, stroke, and cardiovascular death benefits appeared regardless of diabetes status.
Lasting Protection
The reduced risk was consistent across different drugs. Examples include semaglutide, liraglutide, and dulaglutide. Patients also had fewer hospitalizations for heart failure. Their risk of death from any cause dropped as well. The benefits were strongest in high‑risk groups. These include people with obesity, type 2 diabetes, or existing heart disease.
Safe and Tolerable
Serious safety issues did not increase. Severe hypoglycemia and acute pancreatitis were rare. However, gastrointestinal side effects like nausea and vomiting were more common. These effects are already well known.
A New Role for These Drugs
Cardiovascular disease is the leading cause of death worldwide. Using GLP‑1 drugs earlier could prevent thousands of events. “Our results show these medications do much more than control weight,” says lead author Dr. Simon Cork. This evidence supports broader use in healthcare strategies.
